Urgent.News

the world's headlines, one feed

Editions

Business

McDonald's value menu isn't the only thing holding it back

McDonald's CEO said it needs to figure out its value menu. We surveyed readers on what they'd want fixed.

Abstract editorial illustration

McDonald's value menu is not the sole reason for the chain's struggles, as some customers do not find it worthy of their money. CEO Chris Kempczinski admitted that the introduction of a new low-cost menu was a poor move, as it came at a time when the company was reducing digital discounts. A survey conducted by Business Insider revealed that 57% of 227 respondents rated the value they receive from McDonald's as "poor" or "very poor."

One customer stated that the under-$3 menu does not feel like a genuine value, suggesting a price of $1 would make it more appealing. Fast-food restaurants raising prices may lose their competitive edge against higher-end chains like Chipotle and Shake Shack, while casual dining spots like Chili's are offering competitive meal deals.

Additionally, consumers are increasingly focusing on protein content in their meals, aiming to cater to the growing wellness trend. McDonald's launched a dedicated "Protein Picks" section on its app, but the menu does not offer high-protein, low-calorie options effectively. For instance, the 3-piece McCrispy Strips contain 31 grams of protein but have around 400 calories, while Chick-fil-A's eight-piece grilled nuggets have 25 grams of protein at just 130 calories, making it a more attractive option for health-conscious customers.

Written by urgent.news from Business Insider's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

Read the original at businessinsider.com →

More in Business

MSS Prepares Ulchi Exercise to Sustain SME Support

The “2026 Ulchi Exercise,” aimed at maintaining government functions and ensuring public safety in the event of a national emergency, will be conducted from Aug. 18 to 21.

  • Ministry of SMEs and Startups prepares for 2026 Ulchi Exercise.
  • Exercise evaluates support for SMEs during national emergencies.
  • Focus on cyberterrorism and Chungmu Plan sustainability.

Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe

Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution in pre-filled syringe (PFS), a biosimilar referencing Eylea1(aflibercept), across Europe, starting today.“We are…

  • Samsung Bioepis launches OPUVIZ™ 40 mg/mL pre-filled syringe in Europe.
  • Vice President Antonio Rito praises convenience and precision of new format.
  • OPUVIZ approved for wet AMD, macular edema, diabetic edema, and choroidal neovascularisation.